secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001193125-22-283537
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical Q3 commercial rev $9.0M, up 30%; raises FY guidance; pivotal trial endpoints met
--------------------------------------------------------------------------------

- Commercial revenue (ex-BARDA) $9.0M, +30% YoY; total revenue $9.1M.
- Net loss $5.6M ($0.22/sh); cash $88.2M, no debt.
- Soft-tissue repair trial met co-primary endpoints; vitiligo trial achieved super-superiority.
- FY 2022 commercial revenue guidance raised to $33-34M from $30M.
- Japan MHLW grants RECELL approval; partner COSMOTEC launching in Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000119312522283537/0001193125-22-283537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000119312522283537/d384818d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-283537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer